SavedAdd your journal

Journals / İnfeksiyon Dergisi / 2005 / Cilt: 19 - Sayı: 3

The prevalence of hepatitis B virus surface antigen (HBsAg) and anti-hepatitis C virus (Anti-HCV) in type II diabetics

Tip II diyabetli olgularda hepatit B virus yüzey antijeni (HBsAg) ve anti-hepatit C virus (Anti-HCV) prevalansının araştırılması

Ali TAMER
Mustafa TAHTACI
Oğuz KARABAY
Harika ÇELEBİ
Pages
381–383
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In diabetic and control groups, HBsAg positivity rates were 4% and 2.8% (p>0.05) and anti-HCV positivity rates 3.2%, 0.5%, respectively (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to investigate the seroprevalence of hepatitis B virus surface antigen (HBsAg) and anti-hepatitis C virus (anti-HCV) in patients with type II Diabetes mellitus (DM).
📊
Key Findings & Data:The study group consisted of 248 diabetic patients attending the Diabetes Outpatient Clinic, İzzet Baysal Medical Faculty, and the control group consisted of 1208 non-diabetic blood donors.
💡
Conclusion & Impact:In diabetic and control groups, HBsAg positivity rates were 4% and 2.8% (p>0.05) and anti-HCV positivity rates 3.2%, 0.5%, respectively (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The aim of this study was to investigate the seroprevalence of hepatitis B virus surface antigen (HBsAg) and anti-hepatitis C virus (anti-HCV) in patients with type II Diabetes mellitus (DM). The study group consisted of 248 diabetic patients attending the Diabetes Outpatient Clinic, İzzet Baysal Medical Faculty, and the control group consisted of 1208 non-diabetic blood donors. The HBsAg and anti-HCV tests were made with commercial ELISA kits. In diabetic and control groups, HBsAg positivity rates were 4% and 2.8% (p>0.05) and anti-HCV positivity rates 3.2%, 0.5%, respectively (p

Özet

Bu araştırmada, tip II diyabet (DM) olgularındaki Hepatit B virus yüzey antijeni (HBsAg) ve anti-hepatit C virus (anti-HCV) seropozitifiiğinin araştırılarak, elde edilen verilerin kontrol grubuyla karşılaştırılması amaçlanmıştır. Çalışma grupları İzzet Baysal Tıp Fakültesi Diyabet Polikliniği tarafından izlenen tip II DM'ü 248 olgudan, kontrol grubu ise diyabetli olmayan 1208 kan vericisinden oluşturulmuştur. HBsAg ve aAnti-HCV ELISA ile araştırılmıştır. HBsAg pozitifliği diyabetli olgularda ve kontrol grubunda sırasıyla %4 ve %2.8 oranında saptanmıştır (p>0.05). Anti-HCV pozitifliği ise diyabetli olgularda %3.2 ve kontrol grubunda, %0.5 olarak bulun¬muştur (p

🔖

Cite This Article

TAMER, A., TAHTACI, M., KARABAY, O., ÇELEBİ, H. (2022). The prevalence of hepatitis B virus surface antigen (HBsAg) and anti-hepatitis C virus (Anti-HCV) in type II diabetics. İnfeksiyon Dergisi, Cilt: 19 - Sayı: 3, 381–383. https://ajindex.com/articles/546510

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45
  2. WHO World Health Report. 1996 Fighting disease, fostering development. Geneva: World Health Organization. World Health Forum 1997; 18:1-8
  3. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-100
  4. McMahon MM, Bistrian BR. Host defenses and susceptibility to infection in patients with diabetes mellitus. Infect Dis Clin North Am 1995; 9:1 -9
  5. Pozzilli P, Leslie RD. Infection and diabetes: mechanisms and prospects for prevention. Diabet Med 1994; 11: 935-41
  6. Gray H, Wreghitt T, Stratton IM, et al. High prevalence of Hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med 1995; 12: 244-9
  7. Sangiorgio L, Attardo T, Gangemi R, Rubino C, Barone M, Lunetta M. Increased frequency of HCV and HBV infection in type 2 diabetic patients. Diabetes Res Clin Pract 2000; 48: 147-51
  8. Ozsoy MF, Oncul O, Cavuslu S, Erdemoglu A, Emekdas G, Pahsa A. Seroprevalences of hepatitis B and C among health care workers in Turkey. J Viral Hepatol 2003; 10:150-6
  9. Villarejos VM, Visona KA, Gutierrez A, Rodriguez A. Role of saliva, urine and feces in the transmission of type B hepatitis. N Engl J Med 1974; 291: 1375-8
  10. Kim WR, Benson JT, Therneau TM, Torgerson HA, Yawn BP, Melton LJ 3rd. Changing epidemiology of hepatitis B in a U.S. community. Hepatology 2004; 39:811-6
  11. Dovin C, Simon D, Zinelabidine H, Wirquin V, Perllemuter L, Dhumeaux D. An outbreak of hepatitis B in an endocrinology unit traced to a capillary-blood-sampling device. N EnglJ Med 1990; 322: 57-8
  12. Ozyilkan E, Erbaş T, Simsek H, Telatar F, Kayhan B, Telatar H. Increased prevalence of hepatitis C virus antibodies in patients with diabetes mellitus. J Intern Med 1994; 235: 283-4
  13. Custro N, Carroccio A, Ganci A, et al. Glycemic homeostasis in chronic viral hepatitis and liver cirrhosis. Diabetes Mefato 2001;27:476-81
  14. Petit JM, Bour JB, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepato/2001; 35:279-83
  15. Gowans EJ. Distribution of markers of hepatitis C virus infection throughout the body. Semin Liver Dis 2000; 20: 85-102
  16. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-9
  17. Simo R, Hernandez C, Genesca J, Jardi R, Mesa